Blog
RSS FeedPosted by Michael Wonder on 07 Apr 2022
ICER publishes white paper evaluating reforms to orphan drug development, pricing and coverage
7 April 2022 - The white paper presents an analysis of the potential risks and benefits of reforms seeking to ...
Posted by Michael Wonder on 24 Jul 2019
Patients, backed by ‘dark money’ group, get ready to debate Duchenne drug prices. It will not be boring.
24 July 2019 - Meetings of the Institute for Clinical and Economic Review don’t usually get one’s heart pumping. ...
Posted by Michael Wonder on 09 May 2018
Evaluating and valuing drugs for rare conditions: no easy answers
9 May 2018 - We find ourselves in an era of unprecedented growth in the development and use of so-called “orphan” ...
Posted by Michael Wonder on 05 May 2018
Watchdog says Vertex cystic fibrosis drugs are not cost effective, but company calls analysis a ‘sham’
4 May 2018 - The oldest Vertex drug for cystic fibrosis, Kalydeco, lists for $311,000, while the newer treatment Orkambi lists ...
Posted by Michael Wonder on 16 Mar 2018
ICER releases draft evidence report on CFTR modulator therapies for cystic fibrosis
15 March 2018 - Public comment period now open until 12 April; requests to make oral comment during public meeting also ...
Posted by Michael Wonder on 13 Nov 2017
Institute for Clinical and Economic Review announces final modified framework for assessing value of treatments for ultra rare diseases
13 November 2017 - Broader societal considerations and expanded cost-effectiveness ranges will be included for treatments targeting fewer than 10,000 patients. ...
Posted by Michael Wonder on 01 Nov 2017
Institute for Clinical and Economic Review posts draft scoping document to guide review of tezacaftor and lumacaftor for cystic fibrosis
31 October 2017 - Document open to public comment until 20 November 2017. ...
Posted by Michael Wonder on 12 Oct 2017
Institute for Clinical and Economic Review to evaluate cystic fibrosis treatments in upcoming report
12 October 2017 - Report expected to review tezacaftor, lumacaftor, and ivacaftor (Vertex Pharmaceuticals); Open Input accepted until 27 October. ...
Posted by Michael Wonder on 09 Sep 2017
Can a new value framework help ease friction over orphan drug prices?
7 September 2017 - America’s healthcare debate has stalled in Congress, but constructive dialogue and innovation are thriving in specialised ...
Posted by Michael Wonder on 25 Jul 2017
ICER seeks public comment on proposed value assessment framework for treatments that represent a potential major advance for serious ultra-rare conditions
25 July 2017 - ICER’s fundamental approach to value assessment remains constant with proposed changes for special circumstances. ...
Posted by Michael Wonder on 11 May 2017
Institute for Clinical and Economic Review posts briefing paper on assessing the value of drugs for rare conditions
10 May 2017 - Report contains a technical brief on Spinraza and will inform discussions at ICER pricing summit on 31 ...
Posted by Michael Wonder on 07 Feb 2017
Assessing the value of drugs for rare conditions: Institute for Clinical and Economic Review to host orphan drug assessment and pricing summit
7 February 2017 - Discussion will be anchored by an ICER Briefing Paper evaluating the evidence on the comparative clinical effectiveness ...
Posted by Michael Wonder on 26 Jul 2016
ICER release final reports on obeticholic acid for treatment of PBC and NASH
26 July 2016 - The ICER has released two final reports, the first titled Obeticholic Acid for the Treatment of Primary ...